FAIM2 Human shRNA Plasmid Kit (Locus ID 23017)
FAIM2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector
|Product Name||FAIM2 Human shRNA Plasmid Kit (Locus ID 23017)|
|Synonyms||LFG; LFG2; NGP35; NMP35; TMBIM2|
|Kit Components||FAIM2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 23017). 5µg purified plasmid DNA per constructNon-effective 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.|
|RefSeq||NM_012306, XM_005268730, XM_017019040, XM_084780|
|shRNA Design||These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service|
|Performance Guaranteed||OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
|The use of this RNAi has been cited in the following citations:|
Lifeguard inhibition of Fas-mediated apoptosis: A possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells
,Radin, D;Lippa, A;Patel, P;Leonardi, D;,
Biomed. Pharmacother. Feb 2016,PubMed ID 26796280